arrow
J

Johann S. de Bono

royal marsden nhs foundation trust
H指数:160
被引数:13.5万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Exploration of tumor genomics associated with prolonged benefit from or resistance to talazoparib monotherapy in patients with metastatic castration-resistant prostate cancer

探索与转移性去势抵抗性前列腺癌患者从talazoparib单药治疗中获益延长或耐药相关的肿瘤基因组学研究

2026-09-290
OA
Chromosomal instability in circulating tumor cells and cabazitaxel resistance in metastatic castration-resistant prostate cancer

循环肿瘤细胞中的染色体不稳定性与转移性去势抵抗性前列腺癌中的卡巴他赛耐药性

2025-12-220
OA
Corrigendum to “International expert consensus on the clinical integration of circulating tumor cells in solid tumors” [Eur. J. Cancer 231 (2025) 116050]

勘误:“International expert consensus on the clinical integration of circulating tumor cells in solid tumors” [Eur. J. Cancer 231 (2025) 116050]

2025-12-100
PRE
NSD2 targeting reverses plasticity and drug resistance in prostate cancer

NSD2靶向逆转前列腺癌的细胞可塑性和药物抵抗性

Nature
IF48.5
2025-11-260
OA
Talazoparib Monotherapy in Metastatic Castration-resistant Prostate Cancer with DNA Damage Response Alterations—Genomic Features Associated with Response to Therapy

Talazoparib单药治疗具有DNA损伤应答改变的转移性去势抵抗性前列腺癌——与治疗反应相关的基因组特征

2025-10-300
PRE
International expert consensus on the clinical integration of circulating tumor cells in solid tumors

实体瘤中循环肿瘤细胞临床整合的国际专家共识

2025-10-200
PRE
Elucidating molecularly stratified single agent, and combination, therapeutic strategies targeting MCL1 for lethal prostate cancer

阐明靶向MCL1的分子分层单药及联合治疗策略,以治疗致命性前列腺癌

2025-10-080
OAAI
Acute myeloid leukaemia cells express high levels of androgen receptor but do not depend on androgen signaling for survival

急性髓系白血病细胞表达高水平的雄激素受体,但不依赖雄激素信号存活。

Leukemia
IF13.4
2025-09-110
OAAI
Integrated Population Pharmacokinetic, Pharmacodynamic, and Safety Analyses to Inform Dosage Selection in the Clinical Development of the ATR Inhibitor Tuvusertib

整合群体药代动力学、药效动力学和安全性的综合分析,以指导ATR抑制剂Tuvusertib在临床开发中的剂量选择

2025-08-210
OAAI
Final overall survival and safety analyses of the phase 3 PSMAfore trial of [177Lu]Lu-PSMA-617 versus change of androgen receptor pathway inhibitor in taxane-naive patients with metastatic castration-resistant prostate cancer

[177Lu]Lu-PSMA-617与雄激素受体途径抑制剂变化的PSMAfore 3期试验在未接受紫杉烷治疗的转移性去势抵抗性前列腺癌患者中的最终总生存期和安全性分析

2025-07-170
OAAI
Efficacy of Anti-PD-(L)1 Immunotherapy in Patients with DNA Mismatch Repair–deficient Metastatic Castration-resistant Prostate Cancer

PD-(L)1免疫疗法在DNA错配修复缺陷型转移性去势抵抗性前列腺癌患者中的疗效

2025-07-120
OAAI
Defactinib with avutometinib in patients with solid tumors: the phase 1 FRAME trial

德法替尼联合阿瓦替尼治疗实体瘤患者: 1期框架试验

2025-06-270
OAAI
PERSEUS1: An Open-label, Investigator-initiated, Single arm, Phase 2 Trial Testing the Efficacy of Pembrolizumab in Patients with Metastatic Castration-resistant Prostate Cancer with Mismatch Repair Deficiency and Other Immune-sensitive Molecular Subtypes

PERSEUS1:一项开放标签、研究者发起的、单臂、II期临床试验,旨在评估帕博利珠单抗在错配修复缺陷型及其他免疫敏感分子亚型的转移性去势抵抗性前列腺癌患者中的疗效。

2025-06-010
OAAI
Health-related quality of life, pain, and symptomatic skeletal events with [177Lu]Lu-PSMA-617 in patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): an open-label, randomised, phase 3 trial

进展性转移性去势抵抗性前列腺癌患者 [177Lu]Lu-PSMA-617的健康相关生活质量、疼痛和症状性骨骼事件 (PSMAfore): 一项开放标签、随机、3期试验

2025-05-260
PRE
Reply to Felix Melchior, Andreas Pircher, and Isabel Heidegger’s Letter to the Editor re: Johann S. de Bono, Meng He, Chen Shi, et al. Final Overall Survival and Molecular Data Associated with Clinical Outcomes in Patients Receiving Ipatasertib and Abiraterone in the Phase 3 IPATential150 Trial. Eur Urol. 2025;87:468–75

回复Felix Melchior、Andreas Pircher和Isabel Heidegger致编辑的信:关于Johann S. de Bono、Meng He、Chen Shi等人。第3阶段IPATential150试验中接受Ipatasertib和Abiraterone治疗患者的最终总生存期及与临床结局相关的分子数据。欧洲泌尿外科杂志。2025;87:468–75。

2025-04-100
PRE
Corrigendum to “Association of Declining Prostate-specific Antigen Levels with Clinical Outcomes in Patients with Metastatic Castration-resistant Prostate Cancer Receiving [177Lu]Lu-PSMA-617 in the Phase 3 VISION Trial” [Eur. Urol. 86 (2024) 552–562]

勘误:“在III期VISION试验中,接受[177Lu]Lu-PSMA-617治疗的患者中,前列腺特异性抗原水平下降与临床结局的相关性”[Eur. Urol. 86 (2024) 552–562]

2025-04-080
OAAI
Association of Declining Prostate-specific Antigen Levels with Clinical Outcomes in Patients with Metastatic Castration-resistant Prostate Cancer Receiving [177Lu]Lu-PSMA-617 in the Phase 3 VISION Trial

下降的前列腺特异性抗原水平与接受[177Lu]Lu-PSMA-617治疗的三期VISION试验中转移性去势抵抗性前列腺癌患者临床结局的关联

2024-12-010
OAAI